乳腺癌同侧锁骨上淋巴结受累患者多学科治疗后的当代结局
该单中心回顾性研究分析了2014至2019年接受新辅助化疗、手术及辅助放疗的173例cN3c乳腺癌患者,中位随访2.8年。5年OS、SCRFS、LRRFS和RFS分别为73%、95%、86%和50%。
要点
- 综合治疗下5年LRRFS达86%,SCRFS达95%。
- 颈清扫作用有限,残留SCV病灶≥1 cm者5年SCRFS为83%。
核心结论
- 采用辅助放疗联合SCV推量的多学科治疗,cN3c乳腺癌患者5年LRRFS为86%。
- 累积SCV剂量≥60 Gy与OS改善相关,但未显著改善SCRFS、LRRFS或RFS。
- 颈清扫作用有限,SCV推量治疗耐受性良好,应考虑使用。
- 尽管系统治疗进步,近半数患者仍发生远处转移,需密切随访。
研究设计与样本
- 单中心回顾性研究,纳入2014至2019年接受根治性新辅助化疗、手术及辅助放疗的cN3c乳腺癌患者173例。
- 所有患者接受包括SCV淋巴结在内的全面区域放疗,中位随访2.8年。
- 机构指南推荐对已消退和未消退的N3淋巴结分别给予10 Gy和16 Gy推量。
主要发现
- 中位年龄54岁,44%为ER阳性/HER2阴性,58%为T3/4期,6%接受颈清扫,90%累积SCV剂量≥60 Gy。
- 5年OS、SCRFS、LRRFS和RFS分别为73%、95%、86%和50%。
- 多因素分析中,累积SCV剂量≥60 Gy、结外延伸、受体状态和ECOG体能状态与OS相关。
关键数值与推荐
- 机构指南推荐对已消退的N3淋巴结推量10 Gy,未消退者推量16 Gy。
- 化疗后SCV淋巴结≥1 cm且仅接受放疗未行颈清扫者5年SCRFS为83%。
临床怎么用
- 对cN3c乳腺癌患者,辅助放疗应包括SCV推量,累积SCV剂量考虑≥60 Gy以改善OS。
- 颈清扫作用有限,对化疗后残留SCV病灶≥1 cm者单纯放疗仍可获得较高SCRFS。
- SCV推量治疗耐受性良好,应予以考虑。
- 治疗后需密切随访,因近半数患者发生远处转移。
局限性
- 单中心回顾性研究,样本量173例,中位随访仅2.8年。
- 未报告SCV剂量≥60 Gy与SCRFS、LRRFS、RFS无显著关联的具体数值。
- 未提供多因素分析中各变量的风险比及置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with breast cancer and ipsilateral supraclavicular (SCV) node involvement at the time of diagnosis (TNM cN3c) have historically had poor outcomes. Radiation therapy (RT) has an important role because SCV nodes are not routinely surgically dissected. However, optimal locoregional management, contemporary outcomes, and prognostic factors are not well defined. METHODS AND MATERIALS: We reviewed the data of patients with cN3c breast cancer treated at our institution between 2014 and 2019 with curative intent, including neoadjuvant chemotherapy, surgery, and adjuvant RT. All patients received comprehensive regional RT, including to the SCV nodes. Institutional guidelines recommend a 10-Gy or 16-Gy boost to resolved and unresolved N3 nodes, respectively. Overall survival (OS), recurrence-free survival (RFS), locoregional recurrence-free survival (LRRFS), and supraclavicular recurrence-free survival (SCRFS) were analyzed. RESULTS: Data from 173 consecutive patients were analyzed with a median follow-up time of 2.8 years. The median age was 54 years, 76 patients (44%) were estrogen receptor positive/human epidermal growth factor receptor 2 negative, 100 patients (58%) had T3/4 disease, and 10 patients (6%) underwent a neck dissection. In addition, 156 patients (90%) received a cumulative SCV dose of ≥60 Gy. The 5-year OS, SCRFS, LRRFS, and RFS rates were 73%, 95%, 86%, and 50%, respectively. The 5-year OS rate for a cumulative SCV dose of ≥60 Gy versus <60 Gy was 75% versus 39% (P = .04). In the multivariable analysis, a cumulative SCV dose of ≥60 Gy, extranodal extension, receptor status, and Eastern Cooperative Oncology Group performance status were associated with OS. The 5-year SCRFS rates with and without neck dissection were 100% versus 95% (P = .57). Among patients with a postchemotherapy SCV node size of ≥1 cm without neck dissection, the 5-year SCRFS rate was 83%. CONCLUSIONS: In one of the largest series of patients with cN3c breast cancer, multimodality therapy using adjuvant RT with a SCV boost resulted in a 5-year LRRFS rate of 86%. There is a limited role for neck dissection as the 5-year SCRFS rate was 95% overall and 83% for residual SCV disease ≥1 cm after chemotherapy with RT alone. A cumulative SCV dose of ≥60 Gy was associated with improved OS, but not SCRFS, LRRFS, or RFS. A SCV boost should be considered in these patients as treatment was well-tolerated. Despite advances in systemic therapy, nearly half of patients developed distant metastases, highlighting the need for close observation after treatment.
引用
- Diao K, Andring LM, Barcenas CH, et al. Contemporary Outcomes After Multimodality Therapy in Patients With Breast Cancer Presenting With Ipsilateral Supraclavicular Node Involvement. Int J Radiat Oncol Biol Phys. 2021. PMID: 34710521. doi:10.1016/j.ijrobp.2021.08.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。